16th August 2017
Yesterday the Medicines and Healthcare products Regulatory Agency (MHRA) released updated advice for healthcare professionals and people with allergies and their carers on adrenaline auto-injectors (AAIs) following a review of all devices approved in the EU.
The review recommended
- that healthcare professionals prescribe two AAIs, which patients should carry at all times
- that needle length of the AAI device is now stated in the product information
- that manufacturers update their educational materials to help train people with allergies and their carers how to use their AAI
- that manufacturers should carry out studies in humans to more fully understand when and how much adrenaline reaches the blood stream, and how quickly and effectively it acts on body tissues
Anaphylaxis Campaign actively campaigns for people to be prescribed two AAIs. We firmly recommend that once prescribed they should always be kept with the patient so they have access to them at all times in case one is broken or misfires, or a second injection is needed before emergency help arrives. We therefore welcome this expression of support from the MHRA that patients should actively be prescribed two AAIs.
If you or your family member has a severe allergy and has been prescribed an AAI we recommend reading the updated patient advice sheet here.
We also advocate for better training for healthcare professionals and patients and their carers to ensure that everyone thoroughly understands how to use their prescribed device.
We provide specialised training for patients, carers and healthcare professionals via our Allergy Wise online courses. Click here for more information about our accredited courses.